RARE
Ultragenyx Pharmaceutical Inc.Company Information
- Company Name
- Ultragenyx Pharmaceutical Inc.
- CIK
- CIK0001515673
- Category
- Large accelerated filer
- Ticker: Exchange
- RARE: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- RARE
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-09-15
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 151,034
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 103,848,414
- Shares outstanding
- 101,900,000
- Ownership
- 101.91%
Earnings Market Reaction
- Filing date
- 2026-08-05
- Price on filing date
- —
- 1-month reaction
- 2.73%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 125 | 175 | 421 | 203 | 176 | 127 | 174 | 151 | 481 | 112 | 214 | 73 | ||||||
| Available For Sale Securities Debt Securities Current | 167 | 238 | 259 | 223 | 311 | 367 | 436 | 471 | 283 | 300 | 364 | 370 | ||||||
| Accounts Receivable Net Current | 200 | 121 | 158 | 113 | 124 | 99 | 122 | 93 | 106 | 100 | 73 | 79 | ||||||
| Inventory Net | 59 | 55 | 52 | 52 | 46 | 46 | 45 | 43 | 40 | 36 | 34 | 32 | ||||||
| Other Assets Current | - | - | - | - | - | - | - | 41 | 55 | 48 | 48 | - | ||||||
| Prepaid Expense And Other Assets Current | 55 | 68 | 61 | 53 | 61 | 60 | 40 | - | - | - | 48 | 46 | ||||||
| Assets Current | 606 | 657 | 951 | 643 | 720 | 699 | 817 | 800 | 965 | 596 | 732 | 599 | ||||||
| Property Plant And Equipment Net | 235 | 239 | 244 | 250 | 256 | 261 | 266 | 272 | 279 | 285 | 291 | 297 | ||||||
| Available For Sale Securities Debt Securities Noncurrent | 144 | 121 | 57 | 22 | 51 | 69 | 135 | 203 | 111 | 157 | 200 | 82 | ||||||
| Operating Lease Right Of Use Asset | - | - | - | - | - | - | - | - | - | - | - | 26 | ||||||
| Intangible Assets Net Excluding Goodwill | 172 | 174 | 176 | 173 | 175 | 177 | 178 | 165 | 166 | 165 | 166 | 157 | ||||||
| Goodwill | 44 | 44 | 44 | 44 | 44 | 44 | 44 | 44 | 44 | 44 | 44 | 44 | ||||||
| Other Assets Noncurrent | 63 | 61 | 60 | 58 | 60 | 62 | 63 | 54 | 54 | 60 | 58 | 28 | ||||||
| Assets | 1,264 | 1,296 | 1,532 | 1,190 | 1,306 | 1,312 | 1,503 | 1,538 | 1,618 | 1,307 | 1,491 | 1,238 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 39 | 42 | 31 | 41 | 34 | 47 | 39 | 36 | 60 | 41 | 42 | 33 | ||||||
| Accrued Liabilities Current | 221 | 194 | 265 | 221 | 181 | 173 | 241 | 185 | 154 | 149 | 196 | 179 | ||||||
| Operating Lease Liability Current | - | - | 12 | 12 | 12 | 10 | 10 | - | - | - | 13 | - | ||||||
| Other Liabilities Current | 15 | 17 | 7 | 1 | 3 | 3 | 4 | 5 | - | - | 0 | - | ||||||
| Liabilities Current | 351 | 325 | 384 | 340 | 293 | 292 | 344 | 285 | 273 | 246 | 280 | 254 | ||||||
| Operating Lease Liability Noncurrent | - | - | 24 | 22 | 25 | 28 | 30 | - | - | - | 31 | - | ||||||
| Deferred Income Tax Liabilities Net | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 32 | ||||||
| Other Liabilities Noncurrent | 41 | 42 | 20 | 19 | 17 | 17 | 17 | 16 | 15 | 14 | 12 | 10 | ||||||
| Liabilities | 1,548 | 1,525 | 1,605 | 1,174 | 1,148 | 1,161 | 1,241 | 1,185 | 1,186 | 1,167 | 1,216 | 1,206 | ||||||
| Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | - | - | 0 | - | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Treasury Stock Value | -10 | -10 | -8 | -8 | -8 | -8 | -4 | -4 | -3 | -3 | -0 | -0 | ||||||
| Treasury Stock Deferred Employee Stock Ownership Plan | 10 | 10 | 8 | 8 | 8 | 8 | 4 | 4 | 3 | 3 | 0 | 0 | ||||||
| Additional Paid In Capital | 4,518 | 4,481 | 4,451 | 4,412 | 4,374 | 4,252 | 4,213 | 4,169 | 4,123 | 3,699 | 3,662 | 3,298 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | 1 | 1 | -0 | -0 | -1 | 1 | -1 | -0 | 1 | -2 | ||||||
| Retained Earnings Accumulated Deficit | -4,809 | -4,717 | -4,532 | -4,403 | -4,223 | -4,108 | -3,957 | -3,823 | -3,690 | -3,558 | -3,388 | -3,264 | ||||||
| Stockholders Equity | -291 | -236 | -80 | 9 | 151 | 144 | 255 | 347 | 432 | 140 | 275 | 32 | ||||||
| Liabilities And Stockholders Equity | 1,264 | 1,296 | 1,532 | 1,190 | 1,306 | 1,312 | 1,503 | 1,538 | 1,618 | 1,307 | 1,491 | 1,238 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | ||||||
| Preferred Stock Shares Authorized | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | ||||||
| Common Stock Shares Authorized | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | ||||||
| Common Stock Shares Issued | - | - | - | - | - | - | - | - | - | - | - | 72 | ||||||
| Shares Outstanding | 99 | 98 | 97 | 96 | 96 | 94 | 93 | 92 | 92 | 83 | 82 | 72 | ||||||
| Treasury Stock Common Shares | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialUltragenyx Pharmaceutical Inc. (RARE) — SEC Financial Statements & Analysis
Ultragenyx Pharmaceutical Inc. (RARE) is a pharmaceutical preparations company, incorporated in DE. Ultragenyx Pharmaceutical Inc. trades on Nasdaq as: RARE. Ultragenyx Pharmaceutical Inc. (RARE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, Ultragenyx Pharmaceutical Inc. carries a market cap of $3.40B, a P/E ratio of -5.81x, a P/B ratio of -11.69x, a P/S ratio of 4.75x, an enterprise value of $3.28B, and an EV/EBITDA multiple of -6.62x. On profitability, it posts a gross margin of 83.12%, an operating margin of -73.64%, a net margin of -81.73%, a Return on Equity (ROE) of 837.14%, a Return on Assets (ROA) of -45.60%, and a Return on Invested Capital (ROIC) of -1557.09%. Per share, it reports EPS of $-5.75, diluted EPS of $-5.75, free cash flow per share of $-4.80, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 17.51% year-over-year, net income growth of 10.00% year-over-year, and EPS growth of 6.33% year-over-year. On the balance sheet, it maintains a current ratio of 1.73x, a quick ratio of 1.40x, working capital of $255.00M, a debt-to-equity ratio of -5.32x, a debt ratio of 1.22, free cash flow of $-489.00M (TTM), and net debt of $-125.00M. Figures sourced from SEC EDGAR.
- Market Cap
- $3.40B
- P/E TTM
- -5.81x
- EPS TTM
- $-5.75
- P/B TTM
- -11.69x
- ROE TTM
- 837.14%
- ROA TTM
- -45.60%
- Debt To Equity
- -5.32x
- Free Cash Flow TTM
- $-489.00M
- Net Revenue TTM Growth 1Y
- 17.51%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Ultragenyx Pharmaceutical Inc. in?
Ultragenyx Pharmaceutical Inc. (RARE) operates in the Pharmaceutical Preparations industry.
What exchange does RARE trade on?
Ultragenyx Pharmaceutical Inc. (RARE) trades on the Nasdaq.
Where is Ultragenyx Pharmaceutical Inc. incorporated?
Ultragenyx Pharmaceutical Inc. is incorporated in DE.
When was Ultragenyx Pharmaceutical Inc. (RARE)'s most recent SEC filing?
Ultragenyx Pharmaceutical Inc. (RARE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05.
What is RARE's market cap?
Ultragenyx Pharmaceutical Inc. (RARE) has a market capitalization of $3.40B as of 2026-06-30.
What is RARE's EPS (earnings per share)?
Ultragenyx Pharmaceutical Inc. (RARE)'s trailing twelve month EPS is $-5.75 as of 2026-06-30.
What is RARE's ROE (return on equity)?
Ultragenyx Pharmaceutical Inc. (RARE)'s trailing twelve month Return on Equity (ROE) is 837.14% as of 2026-06-30.
What is RARE's ROA (return on assets)?
Ultragenyx Pharmaceutical Inc. (RARE)'s trailing twelve month Return on Assets (ROA) is -45.60% as of 2026-06-30.
What is RARE's ROIC (return on invested capital)?
Ultragenyx Pharmaceutical Inc. (RARE)'s trailing twelve month Return on Invested Capital (ROIC) is -1557.09% as of 2025-03-31.
What is RARE's EV/EBITDA?
Ultragenyx Pharmaceutical Inc. (RARE)'s trailing twelve month EV/EBITDA is -6.62x as of 2026-06-30.